Articles On ImpediMed (ASX:IPD)

Highlights Short interest stays active across ASX mining and tech shares Rare earth and uranium companies remain under close watch Several ASX consumer and financial stocks attract renewed attention Short selling activ...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

If you have a high tolerance for risk, then it could be worth checking out the speculative ASX share in this article. It has been recommended by analysts at Bell Potter, who believe it has the potential to rocket 80% from current levels. Wh...

ASX health sector fell 3.01% for the week, while broader market rose 0.22% Morgans healthcare team has updated research on several stocks following latest reporting season  Owner of Chemist Warehouse chain, Sigma Healthcare, posted strong...

Sigma Health says Chemist Warehouse sales gained traction over the last two months Medibank Private also passes the health test Change at the top for medical pot stock   The owner of the monolithic Chemist Warehouse (CW) chain, Sigma Heal...

ASX closes lower despite eight sectors finishing in the green Staples smashed as Woolies and Coles sold off sharply Lithium keeps climbing on stronger Chinese futures   It’s eight days straight of S&P/ASX 200 blood. The closing clang...

Aroa shares leap 17% after management flags a full-year earnings beat Impedimed hopes GLP-1 drugs will fatten its profits Little Green hits a European purple patch   Kiwi-based wound care house Aroa Biosurgery (ASX:ARX) has defied the glo...

CSL and Mayne Pharma are confident of escaping the impact of Donald Trump’s 100% pharma tariff whack Amplia shares swoon on pancreatic cancer trial setback At the small end of the sector, the CEO revolving door keeps spinning.   CSL’s (AS...

Broker Ord Minnett names its healthcare stocks likely to be high flyers during the current market rout Paradigm Biopharmaceuticals is close to halfway there in its pivotal knee trial – and more than Livin’ on a Prayer Lumos awaits crucial...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

ASX stalwart Cryosite and newbie Vitrafy are having their day in the sun Neuren won’t take European knock-back lying down Entropy beds down its first cohort in its groundbreaking psychedelics trial   Investors are warming to the ASX-liste...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Weekly update on stockbroker recommendation, target price, and earnings forecast cha...

ASX health sector up 0.11% for the week, while broader market rises 0.23% Week dominated by quarterly results with several companies reaching key milestones  Morgans upgrades Imricor after  US FDA breakthrough clearance for its NorthStar M...

The FDA green lights Imricor’s Northstar ‘dashboard’ for controlling MRI-guided ablations Arovella and Painchek achieve FDA breakthroughs As well as soothing pain, Paradigm hopes its knee osteoarthritis drug mends joints   For the second...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Greg Peel It's been a long road for medical device manufacturer ImpediMed, but analysts be...

ASX health sector falls 2.2% for the week as rotation back to sector loses momentum, while broader market up 0.2%  Cochlear backed Epiminder has a disappointing first week on the ASX after its IPO on Monday Mach7 signs a five-year subscrip...

Testing giant ALS has shrugged off weak drug testing revenues to post a 12% half-year profit boost, so it’s no ‘pharmageddon’ Tryptamine’s binge eating psychedelics trial kicks up a gear Impedimed eyes revenue beyond detecting lymphoedema...

Having satisfied the FDA about safety concerns, Neurizon will motor on to the Healey trial platform LTR Pharma invests $1 million in omega-3 side venture Thanks to options, 4D Medical cashes up   Neurizon Therapeutics (ASX:NUZ) is free to...

Impedimed and Avita Medical have won a ‘pay rise’ from private and public US payors Orthocell posts record revenue – an entrée perhaps, with US sales main course to come  Gut disorders house Immuron outlines a packed October schedule   Fe...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

ASX heath sector falls 0.65 % in past five days but returns 9% in July in a strong comeback  ‘Mostly pretty good’ June quarterly reporting season comes to end  Clarity Pharmaceuticals completes $203 million capital raise to institutional i...

ASX health stocks rally 5% over past five days as sector’s largest company CSL rises 6.3% Recruitment completed for a phase II investigator-led study of Clarity’s prostate cancer imaging agent EBR receives preliminary Transitional Pass-Thr...

Lumos Diagnostics says its US distribution deal is worth up to $487 million Impedimed’s US device sales are on a roll Noxopharm treats its first lupus trial patient   In one of the “largest distribution deals of its type” by an ASX-listed...

Tetratherix’s listed life starts on a solid note Dimerix pockets a $4.2 million milestone – with close to $1.4 billion to come Orthocell chalks up first commercial US procedure for its Remplir device Today’s ASX debut of wound management...

By stockpiling components, the US-focused Impedimed is taking no chances with tariffs Cashed-up Amplia forges ahead with promising pancreatic cancer trial Some biotechs are headed to the well, while others are rolling in the green stuff...

Nova Eye and Syntara led today’s biotech relief rally, after the sector sunk on Wednesday on the back of a flagged US pharmaceutical tariff Flu vaccines don’t give you autism, but do they work? Recce is raising up to $15.8 million to fund...

Healthcare leaders stress need for more women in leadership in ASX biotech sector ImpediMed’s female CEO and chair understand challenges for women in sector Dimerix CEO and MD Dr Nina Webster believes workplace flexibility helps women bala...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((LTM)) - Arcad...

Middle East healthcare sector undergoing rapid expansion presenting opportunities for ASX-listed companies ImpediMed has a distributor in Qatar for its SOZO bioimpedance spectroscopy (BIS) device for early detection and prevention of lymph...

Highlights Rapid sector growth offers new prospects for ASX-listed healthcare firms Key players (IPD,DXB,IMR) are enhancing regional presence Rising demand driven by innovation and demographic trends fuels market expansion The healthc...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

ASX health stocks fall 2.8% over past week, while the broader market rose 0.3%  Fisher & Paykel Healthcare could take hit by proposed new US tariffs on Mexico CSL among larger ASX health care names due to report half yearly results nex...

  Percheron has detailed why its Duchenne muscular dystrophy trial flopped – and why it needs to find a new drug candidate Imugene’s multiple oncology and inflammation programs aren’t helping its valuation Impedimed and Micro-X raise funds...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Rudi Filapek-Vandyck By Rudi Filapek-Vandyck, Editor The February results season will soon...

Mixed revenue trends emerge from the latest batch of quarterly updates Proteomics plans to launch its predictive diabetes test next year Chimeric raises $5 million – but drops its daks to do so   As the end-of-October quarterly reporting...

Medical technology company ImpediMed (ASX:IPD) continues to make strides with its SOZO® Digital Health Platform, reporting significant progress in its Q1 FY25 results. The company’s pipeline for SOZO units increased by 34%, with 28 units so...

Control Bionics says it has overcome the “challenges” of the 2023-24 year Ord Minnett identifies the health sector stunners Noxopharm finds a drug manufacturer to kick-start its lupus trial   Health Check is renowned biotech journo Tim Bo...

The ASX is anticipated to experience a slight decline at the opening on Tuesday, following Wall Street's gains as investors analyze comments from U.S. policymakers. At 8 AM AEST, the SPI ASX200 futures contract indicated a decrease of 0.1%....

ASX set for slight drop as investors digest Fed comments Fed officials hint at potential future rate cuts Gold prices hit record highs while Tesla and Boeing rise   The ASX is looking at a slight drop when the market opens on Tuesday desp...

Stockhead joined with IR Department and Morgans for HealthInvest 2024 in Sydney last week The event highlighted some of ASX’s leading and up-and-coming biotech and life sciences companies Imricor Medical Systems, Race Oncology, Clarity Pha...

When I last covered ImpediMed (ASX:IPD) in May last year, I opined that the time-honoured way of lifting team performance was to replace the coach – a ploy that works about as often as it doesn’t. Back then, Rick Valencia had just replaced...

ASX health stocks dropped 1.74% in the past five days, while the broader markets rose 1.55% Power confident US Fed’s 50 basis points cut in cash rate this week will bring more optimism to the sector  Morgans, investor relations firm IR Dep...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Broker Rating Changes (Post Thursday Last Week) Upgrade DOMAIN HOLDINGS AUSTRALIA LI...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Welcome to the FNArena Corporate Results Monitor. Today’s Reports: ((AIS)) – Aeris...

ASX health stocks dropped 1.22% in the past four days, while the broader markets fell 1.35% Morgans downgrades Ramsay Health Care following its FY24 results, believes a ‘near-term earnings recovery looks challenging’ Percheron reports posi...

ASX health stocks flat for week in line while broader markets rise of 0.5% Nanosonics has risen ~17% in the past five days on its FY24 result Mach7 falls falls as investing in growth plans push out profit expectations    Healthcare and li...